1

Duchenne Muscular Dystrophy | Drug Approved for the 3rd Subtype

 News Discuss 
The FDA has approved Sarepta's third exon-skipping medication for the terrible muscle-wasting condition Duchenne muscular dystrophy (DMD).

Comments

    No HTML

    HTML is disabled


    Report Page

Who Upvoted this Story

Search

Published News